

National Cancer Institute  
Institutional Review Board  
**AGENDA\* (revised 11/15/13)**  
**November 18, 2013**  
1:00 – 5:00 pm  
CRC/3-1608

1. **Review of Draft Minutes, November 4, 2013**
2. **Announcements**
3. **Old Business**
4. **New Business**
5. **NIH Problem Reports**
6. **Other Expedited Actions**
  - **Emergency INDs**
7. **Continuing Reviews**
8. **Response to Stips** P131324, "A Phase 2 Study of the MET Kinase Inhibitor INC280 in Papillary Renal Cell Cancer" - Ramaprasad Srinivasan, PI
9. **Amendment** 10D0180-E, "A Pilot Trial Targeting mTOR as a Novel Mechanism-Based Neoadjuvant Therapy for Head and Neck Cancer" - J Silvio Gutkind, Ph.D., PI
10. **Amendment** 11C0160-F, "A Pilot/Phase 2 Study of Pentostatin plus Cyclophosphamide Immune Depletion to Decrease Immunogenicity of SS1P in Patients with Mesothelioma" - Raffit Hassan, PI
11. **Initial Review** P131461, "Sonalleve MR-HIFU for Palliation of Bone Pain: Pilot Study" - Aradhana Venkatesan, PI
12. **\* Initial Review** P131493, "Defibrotide for Patients with Hepatic Veno-Occlusive Disease (VOD): A Treatment IND Study"—Nirali Shah, PI